Informed consent, price transparency, and disclosure
In the American medical system, patients do not know the final price of treatment until long after the treatment is given, at which point it is too late to say “no.” I argue that without price disclosure many, perhaps all, tokens of consent in clinical medicine fall below the standard of valid, info...
| Autor principal: | |
|---|---|
| Tipo de documento: | Recurso Electrónico Artigo |
| Idioma: | Inglês |
| Verificar disponibilidade: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Publicado em: |
2023
|
| Em: |
Bioethics
Ano: 2023, Volume: 37, Número: 8, Páginas: 741-747 |
| Classificações IxTheo: | KBQ América do Norte NCE Ética econômica NCH Ética da medicina |
| Outras palavras-chave: | B
Informed Consent
B price transparency B Disclosure B Cost B Reasonable Person |
| Acesso em linha: |
Presumably Free Access Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| Resumo: | In the American medical system, patients do not know the final price of treatment until long after the treatment is given, at which point it is too late to say “no.” I argue that without price disclosure many, perhaps all, tokens of consent in clinical medicine fall below the standard of valid, informed consent. This is a sweeping and broad thesis. The reason for this thesis is surprisingly simple: medical services rarely have prices attached to them that are known to the patient prior to treatment. Yet, for many patients, knowledge of the price is relevant to whether they would give consent. If informed consent requires that patients know all information about their treatment that is relevant to their decision, then consent to a medical intervention in the absence of the price is not informed consent. |
|---|---|
| ISSN: | 1467-8519 |
| Obras secundárias: | Enthalten in: Bioethics
|
| Persistent identifiers: | DOI: 10.1111/bioe.13206 |
